We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Four Susceptibility Loci Identified for Testicular Germ Cell Tumor

By LabMedica International staff writers
Posted on 08 Nov 2015
Print article
Image: Histopathology of a testicular germ cell tumor consisting of teratoma, embryonal carcinoma yolk sac tumor and syncytiotrophoblasts (Photo courtesy of Lee Moffitt Cancer Center).
Image: Histopathology of a testicular germ cell tumor consisting of teratoma, embryonal carcinoma yolk sac tumor and syncytiotrophoblasts (Photo courtesy of Lee Moffitt Cancer Center).
Testicular germ cell tumor (TGCT) is the most common cancer in men aged 15 to 45 years, with over 18,000 new cases diagnosed annually in Europe and the incidence of TGCT has approximately doubled over the last four decades in Western Europe, which implicates environmental or lifestyle factors as risk determinants.

There are no current treatment options that target specific genetic mutations in testicular cancer, and standard treatment with platinum-based chemotherapy has a high success rate. That means that the more likely application of genetic testing in testicular cancer is in diagnosing the level of risk in men yet to develop it, rather than in matching patients to specific treatments.

Scientists at the Institute of Cancer Research (ICR; London, UK) and their colleagues that carried out a study of more than 25,000 men has uncovered four new genetic variants associated with increased risk of testicular cancer. They discovered four new variants through analyzing the DNA of 6,059 patients with testicular cancer, and comparing it with the DNA of 19,094 people without the disease.

Genotyping for stages 1 and 2 was performed and, stage 1 cases were genotyped on the Illumina HumanCNV370-Duo bead array (Illumina; San Diego, CA, USA) and controls were genotyped on the Illumina Infinium 1.2M array. They used data on 314,861 single nucleotide polymorphism (SNPs) that were successfully genotyped on both the arrays. Stage 2 genotyping was conducted using a custom Illumina Infinium array (iCOGS array) comprising 211,155 SNPs.

These variants, combined with all 21 previously characterized using genetic sequencing, identified men with a 10-fold higher risk of testicular cancer than the population average. Carrying two copies of a single-letter change in the DNA of chromosome 16 led to a 35% increase in activity of the gene glutathione S-transferase pi (GSPT1) in men with testicular cancer, compared with those without. This gene has a role in controlling cell division and has been shown to have increased activity in cancers of the breast, stomach and prostate.

Clare Turnbull, PhD, a senior author of the study said, “Our study identified four new genetic risk factors for testicular cancer. Through previous studies, many led by our team at the ICR, this brings the total number of genetic variants known to be associated with testicular cancer to 25. Applying these 25 variants, we found that men in the top 1% for testicular cancer risk were at a more than ten-fold elevated risk of developing the disease compared with the average—although that still adds up to only around a 5% chance of developing testicular cancer.” The study was published on October 27, 2015, in the journal Nature Communications.

Related Links:

Institute of Cancer Research 
Illumina 


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Automated Nucleic Acid Extractor
eLab
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more